Literature DB >> 22783425

Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution.

Zhi-Gang Liu1, Wei Yi, Ya-Lan Tao, Hsiao Chang Chan, Mu-Sheng Zeng, Yun-Fei Xia.   

Abstract

Aurora-A kinase (Aur-A), a member of a family of mitotic serine/threonine kinases, is known to be amplified in epithelial malignancies. In this study, we focused our investigation on Aur-A expression and its prognostic significance in nasopharyngeal carcinoma (NPC). Immunohistochemical staining for Aur-A was performed on the paraffin sections of 208 patients with NPC. Data were subjected to statistical analysis with respect to clinicopathological variables, overall survival and disease-free survival. An immunohistochemical analysis showed that Aur-A was highly expressed in 132 (63.5%) of the 208 NPC tissues examined. Aur-A expression was significantly correlated with T classification (P=0.012), clinical stage (P=0.003) and skull base invasion (P=0.003). Statistical analysis showed that Aur-A expression was inversely correlated with the 10-year overall and disease-free survival rates of NPC patients. Results of the multivariate analysis revealed that Aur-A expression was an independent prognostic indicator for patient survival. More significantly, Aur-A was found to be a marker for poor survival, which was mainly attributed to its high expression in the subgroup of T(4) tumor classification with aggressive local invasion. These results indicated that Aur-A expression is inversely correlated with survival and directly correlated with the malignant status of NPC. Therefore, Aur-A may serve as a potential biological marker for poor prognosis in the T(4) subgroup of patients.

Entities:  

Year:  2012        PMID: 22783425      PMCID: PMC3392567          DOI: 10.3892/ol.2012.660

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  57 in total

1.  Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.

Authors:  Chi-Long Chen; Da-Liang Ou
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

2.  Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival.

Authors:  Wen-Ting Liao; Li-Bing Song; Hui-Zhong Zhang; Xing Zhang; Ling Zhang; Wan-Li Liu; Yan Feng; Bao-Hong Guo; Hai-Qiang Mai; Su-Mei Cao; Man-Zhi Li; Hai-De Qin; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.

Authors:  Chao-Nan Qian; Xiang Guo; Brian Cao; Eric J Kort; Chong-Chou Lee; Jindong Chen; Ling-Mei Wang; Wei-Yuan Mai; Hua-Qing Min; Ming-Huang Hong; George F Vande Woude; James H Resau; Bin Tean Teh
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

4.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines.

Authors:  S Sen; H Zhou; R A White
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

5.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.

Authors:  R Masunaga; H Kohno; D K Dhar; S Ohno; M Shibakita; S Kinugasa; H Yoshimura; M Tachibana; H Kubota; N Nagasue
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

6.  Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers.

Authors:  Y Miyoshi; K Iwao; C Egawa; S Noguchi
Journal:  Int J Cancer       Date:  2001-05-01       Impact factor: 7.396

7.  The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

Authors:  Eiji Tanaka; Yosuke Hashimoto; Tetsuo Ito; Tomoyuki Okumura; Takatsugu Kan; Go Watanabe; Masayuki Imamura; Johji Inazawa; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

8.  Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.

Authors:  Kai-Ping Chang; Cheng-Lung Hsu; Yu-Liang Chang; Ngan-Ming Tsang; Chin-Kuo Chen; Ta-Jen Lee; Kuo-Chien Tsao; Chung-Guei Huang; Yu-Sun Chang; Jau-Song Yu; Sheng-Po Hao
Journal:  Oral Oncol       Date:  2008-02-21       Impact factor: 5.337

9.  Primary tumor volume of nasopharyngeal carcinoma: significance for survival.

Authors:  Ching-Chih Lee; Hsu-Chueh Ho; Moon-Sing Lee; Shih-Hsuan Hsiao; Juen-Haur Hwang; Shih-Kai Hung; Pesus Chou
Journal:  Auris Nasus Larynx       Date:  2008-01-30       Impact factor: 1.863

10.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

View more
  6 in total

1.  Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma.

Authors:  Pei-Yu Huang; Yan Li; Dong-Hua Luo; Xue Hou; Ting-Ting Zeng; Meng-Qing Li; Hai-Qiang Mai; Li Zhang
Journal:  Strahlenther Onkol       Date:  2015-05-19       Impact factor: 3.621

2.  AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia.

Authors:  ShengYong Long; Xuan Fen Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-23       Impact factor: 4.322

3.  Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.

Authors:  Enke Baldini; Chiara Tuccilli; Natalie Prinzi; Salvatore Sorrenti; Laura Falvo; Corrado De Vito; Antonio Catania; Francesco Tartaglia; Renzo Mocini; Carmela Coccaro; Stefania Alessandrini; Susi Barollo; Caterina Mian; Alessandro Antonelli; Enrico De Antoni; Massimino D'Armiento; Salvatore Ulisse
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

Review 4.  A new aurora in anaplastic thyroid cancer therapy.

Authors:  Enke Baldini; Massimino D'Armiento; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

Review 5.  The functional diversity of Aurora kinases: a comprehensive review.

Authors:  Estelle Willems; Matthias Dedobbeleer; Marina Digregorio; Arnaud Lombard; Paul Noel Lumapat; Bernard Rogister
Journal:  Cell Div       Date:  2018-09-19       Impact factor: 5.130

6.  The New Paradigm of Network Medicine to Analyze Breast Cancer Phenotypes.

Authors:  Anna Maria Grimaldi; Federica Conte; Katia Pane; Giulia Fiscon; Peppino Mirabelli; Simona Baselice; Rosa Giannatiempo; Francesco Messina; Monica Franzese; Marco Salvatore; Paola Paci; Mariarosaria Incoronato
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.